HAWKINS INC (Form: 10-Q, Received: 01/28/2026 16:15:03)

0000046250false2026Q3--03-29xbrli:sharesiso4217:USDiso4217:USDxbrli:shareshwkn:Segmentxbrli:pure00000462502025-03-312025-12-2800000462502026-01-2300000462502025-12-2800000462502025-03-3000000462502025-09-292025-12-2800000462502024-09-302024-12-2900000462502024-04-012024-12-290000046250us-gaap:CommonStockMember2025-03-300000046250us-gaap:AdditionalPaidInCapitalMember2025-03-300000046250us-gaap:RetainedEarningsMember2025-03-300000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-3000000462502025-03-312025-06-290000046250us-gaap:CommonStockMember2025-03-312025-06-290000046250us-gaap:AdditionalPaidInCapitalMember2025-03-312025-06-290000046250us-gaap:RetainedEarningsMember2025-03-312025-06-290000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-312025-06-290000046250us-gaap:CommonStockMember2025-06-290000046250us-gaap:AdditionalPaidInCapitalMember2025-06-290000046250us-gaap:RetainedEarningsMember2025-06-290000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-2900000462502025-06-2900000462502025-06-302025-09-280000046250us-gaap:CommonStockMember2025-06-302025-09-280000046250us-gaap:AdditionalPaidInCapitalMember2025-06-302025-09-280000046250us-gaap:RetainedEarningsMember2025-06-302025-09-280000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-302025-09-280000046250us-gaap:CommonStockMember2025-09-280000046250us-gaap:AdditionalPaidInCapitalMember2025-09-280000046250us-gaap:RetainedEarningsMember2025-09-280000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-2800000462502025-09-280000046250us-gaap:CommonStockMember2025-09-292025-12-280000046250us-gaap:AdditionalPaidInCapitalMember2025-09-292025-12-280000046250us-gaap:RetainedEarningsMember2025-09-292025-12-280000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-292025-12-280000046250us-gaap:CommonStockMember2025-12-280000046250us-gaap:AdditionalPaidInCapitalMember2025-12-280000046250us-gaap:RetainedEarningsMember2025-12-280000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-280000046250us-gaap:CommonStockMember2024-03-310000046250us-gaap:AdditionalPaidInCapitalMember2024-03-310000046250us-gaap:RetainedEarningsMember2024-03-310000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-3100000462502024-03-3100000462502024-04-012024-06-300000046250us-gaap:CommonStockMember2024-04-012024-06-300000046250us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300000046250us-gaap:RetainedEarningsMember2024-04-012024-06-300000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000046250us-gaap:CommonStockMember2024-06-300000046250us-gaap:AdditionalPaidInCapitalMember2024-06-300000046250us-gaap:RetainedEarningsMember2024-06-300000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-3000000462502024-06-3000000462502024-07-012024-09-290000046250us-gaap:CommonStockMember2024-07-012024-09-290000046250us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-290000046250us-gaap:RetainedEarningsMember2024-07-012024-09-290000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-290000046250us-gaap:CommonStockMember2024-09-290000046250us-gaap:AdditionalPaidInCapitalMember2024-09-290000046250us-gaap:RetainedEarningsMember2024-09-290000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-2900000462502024-09-290000046250us-gaap:CommonStockMember2024-09-302024-12-290000046250us-gaap:AdditionalPaidInCapitalMember2024-09-302024-12-290000046250us-gaap:RetainedEarningsMember2024-09-302024-12-290000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-302024-12-290000046250us-gaap:CommonStockMember2024-12-290000046250us-gaap:AdditionalPaidInCapitalMember2024-12-290000046250us-gaap:RetainedEarningsMember2024-12-290000046250us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-2900000462502024-12-290000046250hwkn:WaterSurplusInc.Member2025-04-252025-04-250000046250hwkn:WaterSurplusInc.Member2025-04-250000046250hwkn:WaterSurplusInc.Memberus-gaap:CustomerListsMember2025-04-250000046250hwkn:WaterSurplusInc.Memberus-gaap:TradeNamesMember2025-04-250000046250hwkn:WaterSurplusInc.Memberus-gaap:OtherIntangibleAssetsMember2025-04-250000046250hwkn:WaterSurplusInc.Member2025-09-292025-12-280000046250hwkn:WaterSurplusInc.Member2024-09-302024-12-290000046250hwkn:WaterSurplusInc.Member2025-03-312025-12-280000046250hwkn:WaterSurplusInc.Member2024-04-012024-12-290000046250hwkn:WaterSurplusInc.Member2025-12-280000046250hwkn:AmerochemCorporationMember2025-06-302025-09-280000046250hwkn:WaterguardInc.Member2025-03-312025-06-290000046250hwkn:IntercoastalTradingInc.Member2024-09-302024-12-290000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:WaterTreatmentMember2025-09-292025-12-280000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:FoodHealthSciencesMember2025-09-292025-12-280000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:IndustrialSolutionsMember2025-09-292025-12-280000046250hwkn:ManufacturedBlendedOrRepackagedProductsMember2025-09-292025-12-280000046250hwkn:BulkProductsMemberhwkn:WaterTreatmentMember2025-09-292025-12-280000046250hwkn:BulkProductsMemberhwkn:FoodHealthSciencesMember2025-09-292025-12-280000046250hwkn:BulkProductsMemberhwkn:IndustrialSolutionsMember2025-09-292025-12-280000046250hwkn:BulkProductsMember2025-09-292025-12-280000046250hwkn:NutritionMemberhwkn:WaterTreatmentMember2025-09-292025-12-280000046250hwkn:NutritionMemberhwkn:FoodHealthSciencesMember2025-09-292025-12-280000046250hwkn:NutritionMemberhwkn:IndustrialSolutionsMember2025-09-292025-12-280000046250hwkn:NutritionMember2025-09-292025-12-280000046250hwkn:FoodMemberhwkn:WaterTreatmentMember2025-09-292025-12-280000046250hwkn:FoodMemberhwkn:FoodHealthSciencesMember2025-09-292025-12-280000046250hwkn:FoodMemberhwkn:IndustrialSolutionsMember2025-09-292025-12-280000046250hwkn:FoodMember2025-09-292025-12-280000046250hwkn:PharmaceuticalMemberhwkn:WaterTreatmentMember2025-09-292025-12-280000046250hwkn:PharmaceuticalMemberhwkn:FoodHealthSciencesMember2025-09-292025-12-280000046250hwkn:PharmaceuticalMemberhwkn:IndustrialSolutionsMember2025-09-292025-12-280000046250hwkn:PharmaceuticalMember2025-09-292025-12-280000046250hwkn:AgriculturalMemberhwkn:WaterTreatmentMember2025-09-292025-12-280000046250hwkn:AgriculturalMemberhwkn:FoodHealthSciencesMember2025-09-292025-12-280000046250hwkn:AgriculturalMemberhwkn:IndustrialSolutionsMember2025-09-292025-12-280000046250hwkn:AgriculturalMember2025-09-292025-12-280000046250hwkn:OtherMemberhwkn:WaterTreatmentMember2025-09-292025-12-280000046250hwkn:OtherMemberhwkn:FoodHealthSciencesMember2025-09-292025-12-280000046250hwkn:OtherMemberhwkn:IndustrialSolutionsMember2025-09-292025-12-280000046250hwkn:OtherMember2025-09-292025-12-280000046250hwkn:WaterTreatmentMember2025-09-292025-12-280000046250hwkn:FoodHealthSciencesMember2025-09-292025-12-280000046250hwkn:IndustrialSolutionsMember2025-09-292025-12-280000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:WaterTreatmentMember2024-09-302024-12-290000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:FoodHealthSciencesMember2024-09-302024-12-290000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:IndustrialSolutionsMember2024-09-302024-12-290000046250hwkn:ManufacturedBlendedOrRepackagedProductsMember2024-09-302024-12-290000046250hwkn:BulkProductsMemberhwkn:WaterTreatmentMember2024-09-302024-12-290000046250hwkn:BulkProductsMemberhwkn:FoodHealthSciencesMember2024-09-302024-12-290000046250hwkn:BulkProductsMemberhwkn:IndustrialSolutionsMember2024-09-302024-12-290000046250hwkn:BulkProductsMember2024-09-302024-12-290000046250hwkn:NutritionMemberhwkn:WaterTreatmentMember2024-09-302024-12-290000046250hwkn:NutritionMemberhwkn:FoodHealthSciencesMember2024-09-302024-12-290000046250hwkn:NutritionMemberhwkn:IndustrialSolutionsMember2024-09-302024-12-290000046250hwkn:NutritionMember2024-09-302024-12-290000046250hwkn:FoodMemberhwkn:WaterTreatmentMember2024-09-302024-12-290000046250hwkn:FoodMemberhwkn:FoodHealthSciencesMember2024-09-302024-12-290000046250hwkn:FoodMemberhwkn:IndustrialSolutionsMember2024-09-302024-12-290000046250hwkn:FoodMember2024-09-302024-12-290000046250hwkn:PharmaceuticalMemberhwkn:WaterTreatmentMember2024-09-302024-12-290000046250hwkn:PharmaceuticalMemberhwkn:FoodHealthSciencesMember2024-09-302024-12-290000046250hwkn:PharmaceuticalMemberhwkn:IndustrialSolutionsMember2024-09-302024-12-290000046250hwkn:PharmaceuticalMember2024-09-302024-12-290000046250hwkn:AgriculturalMemberhwkn:WaterTreatmentMember2024-09-302024-12-290000046250hwkn:AgriculturalMemberhwkn:FoodHealthSciencesMember2024-09-302024-12-290000046250hwkn:AgriculturalMemberhwkn:IndustrialSolutionsMember2024-09-302024-12-290000046250hwkn:AgriculturalMember2024-09-302024-12-290000046250hwkn:OtherMemberhwkn:WaterTreatmentMember2024-09-302024-12-290000046250hwkn:OtherMemberhwkn:FoodHealthSciencesMember2024-09-302024-12-290000046250hwkn:OtherMemberhwkn:IndustrialSolutionsMember2024-09-302024-12-290000046250hwkn:OtherMember2024-09-302024-12-290000046250hwkn:WaterTreatmentMember2024-09-302024-12-290000046250hwkn:FoodHealthSciencesMember2024-09-302024-12-290000046250hwkn:IndustrialSolutionsMember2024-09-302024-12-290000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:WaterTreatmentMember2025-03-312025-12-280000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:FoodHealthSciencesMember2025-03-312025-12-280000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:IndustrialSolutionsMember2025-03-312025-12-280000046250hwkn:ManufacturedBlendedOrRepackagedProductsMember2025-03-312025-12-280000046250hwkn:BulkProductsMemberhwkn:WaterTreatmentMember2025-03-312025-12-280000046250hwkn:BulkProductsMemberhwkn:FoodHealthSciencesMember2025-03-312025-12-280000046250hwkn:BulkProductsMemberhwkn:IndustrialSolutionsMember2025-03-312025-12-280000046250hwkn:BulkProductsMember2025-03-312025-12-280000046250hwkn:NutritionMemberhwkn:WaterTreatmentMember2025-03-312025-12-280000046250hwkn:NutritionMemberhwkn:FoodHealthSciencesMember2025-03-312025-12-280000046250hwkn:NutritionMemberhwkn:IndustrialSolutionsMember2025-03-312025-12-280000046250hwkn:NutritionMember2025-03-312025-12-280000046250hwkn:FoodMemberhwkn:WaterTreatmentMember2025-03-312025-12-280000046250hwkn:FoodMemberhwkn:FoodHealthSciencesMember2025-03-312025-12-280000046250hwkn:FoodMemberhwkn:IndustrialSolutionsMember2025-03-312025-12-280000046250hwkn:FoodMember2025-03-312025-12-280000046250hwkn:PharmaceuticalMemberhwkn:WaterTreatmentMember2025-03-312025-12-280000046250hwkn:PharmaceuticalMemberhwkn:FoodHealthSciencesMember2025-03-312025-12-280000046250hwkn:PharmaceuticalMemberhwkn:IndustrialSolutionsMember2025-03-312025-12-280000046250hwkn:PharmaceuticalMember2025-03-312025-12-280000046250hwkn:AgriculturalMemberhwkn:WaterTreatmentMember2025-03-312025-12-280000046250hwkn:AgriculturalMemberhwkn:FoodHealthSciencesMember2025-03-312025-12-280000046250hwkn:AgriculturalMemberhwkn:IndustrialSolutionsMember2025-03-312025-12-280000046250hwkn:AgriculturalMember2025-03-312025-12-280000046250hwkn:OtherMemberhwkn:WaterTreatmentMember2025-03-312025-12-280000046250hwkn:OtherMemberhwkn:FoodHealthSciencesMember2025-03-312025-12-280000046250hwkn:OtherMemberhwkn:IndustrialSolutionsMember2025-03-312025-12-280000046250hwkn:OtherMember2025-03-312025-12-280000046250hwkn:WaterTreatmentMember2025-03-312025-12-280000046250hwkn:FoodHealthSciencesMember2025-03-312025-12-280000046250hwkn:IndustrialSolutionsMember2025-03-312025-12-280000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:WaterTreatmentMember2024-04-012024-12-290000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:FoodHealthSciencesMember2024-04-012024-12-290000046250hwkn:ManufacturedBlendedOrRepackagedProductsMemberhwkn:IndustrialSolutionsMember2024-04-012024-12-290000046250hwkn:ManufacturedBlendedOrRepackagedProductsMember2024-04-012024-12-290000046250hwkn:BulkProductsMemberhwkn:WaterTreatmentMember2024-04-012024-12-290000046250hwkn:BulkProductsMemberhwkn:FoodHealthSciencesMember2024-04-012024-12-290000046250hwkn:BulkProductsMemberhwkn:IndustrialSolutionsMember2024-04-012024-12-290000046250hwkn:BulkProductsMember2024-04-012024-12-290000046250hwkn:NutritionMemberhwkn:WaterTreatmentMember2024-04-012024-12-290000046250hwkn:NutritionMemberhwkn:FoodHealthSciencesMember2024-04-012024-12-290000046250hwkn:NutritionMemberhwkn:IndustrialSolutionsMember2024-04-012024-12-290000046250hwkn:NutritionMember2024-04-012024-12-290000046250hwkn:FoodMemberhwkn:WaterTreatmentMember2024-04-012024-12-290000046250hwkn:FoodMemberhwkn:FoodHealthSciencesMember2024-04-012024-12-290000046250hwkn:FoodMemberhwkn:IndustrialSolutionsMember2024-04-012024-12-290000046250hwkn:FoodMember2024-04-012024-12-290000046250hwkn:PharmaceuticalMemberhwkn:WaterTreatmentMember2024-04-012024-12-290000046250hwkn:PharmaceuticalMemberhwkn:FoodHealthSciencesMember2024-04-012024-12-290000046250hwkn:PharmaceuticalMemberhwkn:IndustrialSolutionsMember2024-04-012024-12-290000046250hwkn:PharmaceuticalMember2024-04-012024-12-290000046250hwkn:AgriculturalMemberhwkn:WaterTreatmentMember2024-04-012024-12-290000046250hwkn:AgriculturalMemberhwkn:FoodHealthSciencesMember2024-04-012024-12-290000046250hwkn:AgriculturalMemberhwkn:IndustrialSolutionsMember2024-04-012024-12-290000046250hwkn:AgriculturalMember2024-04-012024-12-290000046250hwkn:OtherMemberhwkn:WaterTreatmentMember2024-04-012024-12-290000046250hwkn:OtherMemberhwkn:FoodHealthSciencesMember2024-04-012024-12-290000046250hwkn:OtherMemberhwkn:IndustrialSolutionsMember2024-04-012024-12-290000046250hwkn:OtherMember2024-04-012024-12-290000046250hwkn:WaterTreatmentMember2024-04-012024-12-290000046250hwkn:FoodHealthSciencesMember2024-04-012024-12-290000046250hwkn:IndustrialSolutionsMember2024-04-012024-12-290000046250us-gaap:FairValueInputsLevel1Member2025-12-280000046250us-gaap:FairValueInputsLevel1Member2025-03-300000046250us-gaap:FairValueInputsLevel2Member2025-12-280000046250us-gaap:FairValueInputsLevel2Member2025-03-300000046250hwkn:WaterSurplusInc.Memberus-gaap:FairValueInputsLevel3Member2025-12-280000046250hwkn:WaterSurplusInc.Memberus-gaap:FairValueInputsLevel3Member2025-03-300000046250hwkn:WaterSolutionsMemberus-gaap:FairValueInputsLevel3Member2025-12-280000046250hwkn:WaterSolutionsMemberus-gaap:FairValueInputsLevel3Member2025-03-300000046250us-gaap:FairValueInputsLevel3Member2025-03-300000046250hwkn:WaterSurplusInc.Memberus-gaap:FairValueInputsLevel3Member2025-03-312025-12-280000046250hwkn:WaterSolutionsMemberus-gaap:FairValueInputsLevel3Member2025-03-312025-12-280000046250us-gaap:FairValueInputsLevel3Member2025-12-280000046250hwkn:WaterTreatmentMember2025-03-300000046250hwkn:FoodHealthSciencesMember2025-03-300000046250hwkn:IndustrialSolutionsMember2025-03-300000046250hwkn:WaterTreatmentMember2025-12-280000046250hwkn:FoodHealthSciencesMember2025-12-280000046250hwkn:IndustrialSolutionsMember2025-12-280000046250us-gaap:CustomerRelationshipsMember2025-12-280000046250us-gaap:CustomerRelationshipsMember2025-03-300000046250us-gaap:TrademarksMember2025-12-280000046250us-gaap:TrademarksMember2025-03-300000046250us-gaap:OtherIntangibleAssetsMember2025-12-280000046250us-gaap:OtherIntangibleAssetsMember2025-03-300000046250srt:MinimumMember2025-12-280000046250srt:MaximumMember2025-12-280000046250us-gaap:PerformanceSharesMember2025-03-300000046250us-gaap:PerformanceSharesMember2025-03-312025-12-280000046250us-gaap:PerformanceSharesMember2025-12-280000046250us-gaap:PerformanceSharesMember2024-09-302024-12-290000046250us-gaap:PerformanceSharesMember2025-09-292025-12-280000046250us-gaap:PerformanceSharesMember2024-04-012024-12-290000046250us-gaap:RestrictedStockMember2025-12-280000046250us-gaap:RestrictedStockMember2024-09-302024-12-290000046250us-gaap:RestrictedStockMember2025-09-292025-12-280000046250us-gaap:RestrictedStockMember2024-04-012024-12-290000046250us-gaap:RestrictedStockMember2025-03-312025-12-280000046250hwkn:WaterSurplusInc.Member2025-12-280000046250hwkn:WaterSurplusInc.Member2025-09-292025-12-280000046250hwkn:WaterSurplusInc.Member2025-03-312025-12-280000046250hwkn:WaterSurplusInc.Member2024-09-302024-12-290000046250hwkn:WaterSurplusInc.Member2024-04-012024-12-290000046250hwkn:WaterTreatmentMember2024-12-290000046250hwkn:FoodHealthSciencesMember2024-12-290000046250hwkn:IndustrialSolutionsMember2024-12-290000046250hwkn:UnallocatedMember2025-12-280000046250hwkn:UnallocatedMember2024-12-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q


☒			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
			SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 28, 2025


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
			SECURITIES EXCHANGE ACT OF 1934

Commission file number 0-7647


HAWKINS, INC.
(Exact name of registrant as specified in its charter)


Minnesota						41-0771293
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)


2381 Rosegate, Roseville, Minnesota			55113
(Address of principal executive offices)			(Zip code)


(612) 331-6910
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.01 per share	HWKN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☒

Accelerated filer

☐

Non-accelerated filer

☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.


CLASS						Shares Outstanding at January 23, 2026
Common Stock, par value $.01 per share						20,902,093

HAWKINS, INC.

INDEX TO FORM 10-Q


		Page

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements (unaudited):

	Condensed Consolidated Balance Sheets – December 28, 2025 and March 30 , 2025	1

	Condensed Consolidated Statements of Income – Three and Nine Months Ended December 28 , 2025 and Dece m be r 29 , 2024	2

	Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended December 28 , 2025 and December 29 , 2024	3

	Condensed Consolidated Statements of Shareholders' Equity – Three and Nine Months Ended December 28 , 2025 and December 29 , 2024	4

	Condensed Consolidated Statements of Cash Flows – Nine Months Ended December 28 , 2025 and December 29 , 2024	6

	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	19

Item 4.	Controls and Procedures	19

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	20

Item 1A.	Risk Factors	20

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20

Item 3.	Defaults Upon Senior Securities	20

Item 4.	Mine Safety Disclosures	20

Item 5.	Other Information	20

Item 6.	Exhibits	21

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

HAWKINS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(In thousands, except share data)


	December 28, 2025		March 30, 2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	8,209	$	5,103
Trade accounts receivables, net	123,742		131,795
Inventories	85,933		83,512
Income taxes receivable	—		2,864
Prepaid expenses and other current assets	10,319		7,417
Total current assets	228,203		230,691
PROPERTY, PLANT, AND EQUIPMENT:	468,594		420,953
Less accumulated depreciation	215,610		195,667
Net property, plant, and equipment	252,984		225,286
OTHER ASSETS:
Right-of-use assets	17,598		13,449
Goodwill	223,035		135,409
Intangible assets, net of accumulated amortization	238,381		150,121
Deferred compensation plan asset	14,250		11,185
Other	2,075		3,726
Total other assets	495,339		313,890
Total assets	$	976,526	$	769,867
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable — trade	$	46,384	$	61,195
Accrued payroll and employee benefits	20,814		19,659
Income tax payable	1,986		—
Current portion of long-term debt	9,812		9,913

Environmental remediation	7,700		7,700
Other current liabilities	10,459		8,668
Total current liabilities	97,155		107,135
LONG-TERM LIABILITIES:
Long-term debt, less current portion	253,375		138,906
Long-term lease liability	15,100		10,920
Pension withdrawal liability	2,862		3,155
Deferred income taxes	22,061		22,356
Deferred compensation liability	15,829		13,132
Earnout liabilities	50,837		12,604
Other long-term liabilities	401		1,367
Total long-term liabilities	360,465		202,440
Total liabilities	457,620		309,575
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Common stock; authorized: 60,000,000 shares of $0.01 par value; 20,740,284 and 20,684,621 shares issued and outstanding as of December 28, 2025 and March 30, 2025, respectively	207		207
Additional paid-in capital	29,112		24,094
Retained earnings	488,652		434,259
Accumulated other comprehensive income	935		1,732
Total shareholders’ equity	518,906		460,292
Total liabilities and shareholders’ equity	$	976,526	$	769,867

See accompanying notes to condensed consolidated financial statements.

HAWKINS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(In thousands, except share and per-share data)


	Three months ended				Nine months ended
	December 28, 2025		December 29, 2024		December 28, 2025		December 29, 2024
Sales	$	244,080	$	226,205	$	817,786	$	729,113
Cost of sales	(193,267)		(177,781)		(626,968)		(555,812)

Gross profit	50,813		48,424		190,818		173,301
Selling, general and administrative expenses	(28,257)		(27,361)		(92,989)		(78,702)
Operating income	22,556		21,063		97,829		94,599
Interest expense, net	(3,434)		(1,216)		(10,535)		(3,906)
Other income	459		436		2,122		1,268
Income before income taxes	19,581		20,283		89,416		91,961
Income tax expense	(5,269)		(5,262)		(23,331)		(23,943)
Net income	$	14,312	$	15,021	$	66,085	$	68,018

Weighted average number of shares outstanding - basic	20,740,284		20,766,764		20,731,837		20,780,213
Weighted average number of shares outstanding - diluted	20,843,980		20,875,387		20,850,721		20,902,456

Basic earnings per share	$	0.69	$	0.72	$	3.19	$	3.27
Diluted earnings per share	$	0.69	$	0.72	$	3.17	$	3.25

Cash dividends declared per common share	$	0.19	$	0.18	$	0.56	$	0.52

See accompanying notes to condensed consolidated financial statements.

HAWKINS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(In thousands)


	Three months ended				Nine months ended
	December 28, 2025		December 29, 2024		December 28, 2025		December 29, 2024
Net income	$	14,312	$	15,021	$	66,085	$	68,018
Other comprehensive income, net of tax:

Unrealized (loss) gain on interest rate swap	(256)		629		(797)		(807)


Total comprehensive income	$	14,056	$	15,650	$	65,288	$	67,211

See accompanying notes to condensed consolidated financial statements.

HAWKINS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY (UNAUDITED)

(In thousands, except share data)


	Common Stock			Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Total Shareholders’ Equity
	Shares	Amount
BALANCE — March 30, 2025	20,684,621	$	207	$	24,094	$	434,259	$	1,732	$	460,292
Cash dividends declared and paid ($0.18 per share)	—	—		—		(3,754)		—		(3,754)
Share-based compensation expense	—	—		2,212		—		—		2,212
Vesting of restricted stock	61,819	—		(1)		—		—		(1)
Shares surrendered for payroll taxes	(28,590)	—		(3,028)		—		—		(3,028)


Other comprehensive loss, net of tax	—	—		—		—		(324)		(324)
Net income	—	—		—		29,175		—		29,175
BALANCE — June 29, 2025	20,717,850	$	207	$	23,277	$	459,680	$	1,408	$	484,572
Cash dividends declared and paid ($0.19 per share)	—	—		—		(3,969)		—		(3,969)
Share-based compensation expense	—	—		2,375		—		—		2,375
Vesting of restricted stock	6,734	—		—		—		—		—

ESPP shares issued	15,700	—		1,609		—		—		1,609

Other comprehensive loss, net of tax	—	—		—		—		(217)		(217)
Net income	—	—		—		22,598		—		22,598
BALANCE — September 28, 2025	20,740,284	$	207	$	27,261	$	478,309	$	1,191	$	506,968
Cash dividends declared and paid ($0.19 per share)	—	—		—		(3,969)		—		(3,969)
Share-based compensation expense	—	—		1,851		—		—		1,851




Other comprehensive loss, net of tax	—	—		—		—		(256)		(256)
Net income	—	—		—		14,312		—		14,312
BALANCE — December 28, 2025	20,740,284	$	207	$	29,112	$	488,652	$	935	$	518,906


	Common Stock			Additional Paid-in Capital		Retained Earnings		Accumulated Other Comprehensive Income (Loss)		Total Shareholders’ Equity
	Shares	Amount
BALANCE — March 31, 2024	20,790,261	$	208	$	38,154	$	364,549	$	3,115	$	406,026
Cash dividends declared and paid ($0.16 per share)	—	—		—		(3,358)		—		(3,358)
Share-based compensation expense	—	—		1,467		—		—		1,467
Vesting of restricted stock	83,658	1		(1)		—		—		—
Shares surrendered for payroll taxes	(34,047)	(1)		(2,540)		—		—		(2,541)

Shares repurchased	(105,541)	(1)		(9,148)		—		—		(9,149)
Other comprehensive income, net of tax	—	—		—		—		(106)		(106)
Net income	—	—		—		28,879		—		28,879
BALANCE — June 30, 2024	20,734,331	$	207	$	27,932	$	390,070	$	3,009	$	421,218
Cash dividends declared and paid ($0.18 per share)	—	—		—		(3,763)		—		(3,763)
Share-based compensation expense	—	—		1,832		—		—		1,832
Vesting of restricted stock	10,647	—		—		—		—		—

ESPP shares issued	21,786	1		1,296		—		—		1,297

Other comprehensive income, net of tax	—	—		—		—		(1,330)		(1,330)
Net income	—	—		—		24,118		—		24,118
BALANCE — September 29, 2024	20,766,764	$	208	$	31,060	$	410,425	$	1,679	$	443,372
Cash dividends declared and paid ($0.18 per share)	—	—		—		(3,764)		—		(3,764)
Share-based compensation expense	—	—		1,723		—		—		1,723




Other comprehensive income, net of tax	—	—		—		—		629		629
Net income	—	—		—		15,021		$	—	15,021
BALANCE — December 29, 2024	20,766,764	$	208	$	32,783	$	421,682	$	2,308	$	456,981

See accompanying notes to condensed consolidated financial statements.

HAWKINS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In thousands)


	Nine months ended
	December 28, 2025		December 29, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	66,085	$	68,018
Reconciliation to cash flows:
Depreciation and amortization	38,963		29,368
Change in fair value of earnout liabilities	(4,767)		1,027
Operating leases	2,921		2,557

Gain on deferred compensation assets	(2,122)		(1,268)

Stock compensation expense	6,438		5,022

Other	(35)		(4)
Changes in operating accounts providing (using) cash:
Trade receivables	12,811		6,157
Inventories	2,319		(5,682)
Accounts payable	(17,576)		(16,026)
Accrued liabilities	790		(1,698)
Lease liabilities	(2,780)		(2,565)
Income taxes	4,850		(2,636)
Other	(1,305)		(2,018)
Net cash provided by operating activities	106,592		80,252
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant, and equipment	(38,663)		(30,008)


Acquisitions	(167,108)		(43,400)
Other	1,160		586
Net cash used in investing activities	(204,611)		(72,822)
CASH FLOWS FROM FINANCING ACTIVITIES:
Cash dividends declared and paid	(11,692)		(10,885)
New shares issued	1,609		1,297
Payroll taxes paid in exchange for shares withheld	(3,028)		(2,541)


Shares repurchased	—		(9,149)

Payments on revolving loan	(55,000)		(50,000)
Payments for debt issuance costs	(764)		—
Proceeds from revolving loan borrowings	170,000		65,000
Net cash provided by (used in) financing activities	101,125		(6,278)
NET INCREASE IN CASH AND CASH EQUIVALENTS	3,106		1,152
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	5,103		7,153
CASH AND CASH EQUIVALENTS, END OF PERIOD	$	8,209	$	8,305

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash paid for income taxes	$	18,481	$	26,566
Cash paid for interest	$	10,665	$	4,208
Noncash investing activities - capital expenditures in accounts payable	$	827	$	1,152

See accompanying notes to condensed consolidated financial statements.

HAWKINS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Note 1 – Summary of Significant Accounting Policies

Basis of Presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions for Form 10-Q and, accordingly, do not include all information and footnotes required by generally accepted accounting principles for complete financial statements. These financial statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the fiscal year ended March 30, 2025, previously filed with the Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly our financial position and the results of our operations and cash flows for the periods presented. All adjustments made to the interim condensed consolidated financial statements were of a normal recurring nature. All significant intercompany accounts and transactions have been eliminated in consolidation. The results of operations for the nine months ended December 28, 2025 are not necessarily indicative of the results that may be expected for the full year.

As used in this Form 10-Q, except where otherwise stated or indicated by the context, "Hawkins," "we," "us," the Company," or "our" means Hawkins, Inc. and its subsidiaries. References to "fiscal 2024" refer to the fiscal year ended March 31, 2024, references to "fiscal 2025" refer to the fiscal year ended March 30, 2025, and references to "fiscal 2026" refer to the fiscal year ending March 29, 2026.

Effective beginning with the first quarter of fiscal 2026, we realigned our reporting segments to reflect how we manage our operations and allocate resources. We believe this realignment better reflects the value our company provides to our customers and our evolution from a bulk commodity distributor into a specialty ingredients company. We now organize and manage our business by the following three segments, each of which meets the definition of reportable segments under ASC 280-10, Segment Reporting: Water Treatment, Food & Health Sciences, and Industrial Solutions. These segments are defined primarily by product and type of customer. Information presented in this quarterly report has been recast to align with the new segments. Additional information regarding these new segments is set forth in Note 13 - Segment Information.

Use of Estimates. The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, particularly receivables, inventories, property, plant and equipment, right-of-use assets, goodwill, intangibles, accrued expenses, short-term and long-term lease liability, income taxes and related accounts and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Accounting Policies. The accounting policies we follow are set forth in Note 1 – Nature of Business and Significant Accounting Policies to our consolidated financial statements in our Annual Report on Form 10-K for fiscal 2025, previously filed with the SEC. There have been no significant changes in our accounting policies since the end of fiscal 2025.

Recently Issued Accounting Pronouncements

Income Taxes (Topic 740): Improvements to Income Tax Disclosures (ASU No.2023-09)

In December 2023, the Financial Accounting Standards Board ("FASB") issued accounting standards update No. 2023-09 to enhance the transparency and decision-usefulness of income tax disclosures and to provide information to better assess how an entity's operations and related tax risks and tax planning and operational opportunities affect its tax rate and prospects for future cash flows. For public business entities, the amendments in this update are effective for annual periods beginning after December 15, 2024, our fiscal 2026. The adoption of ASU No. 2023-09 is not expected to have a material impact on our consolidated financial statements but will require a lower level of disclosure in our Form 10-K for fiscal 2026 and in periodic reports thereafter.

Disaggregation of Income Statement Expenses (ASU No.2024-03)

In November 2024, the FASB issued ASU 2024-03, Disaggregation of Income Statement Expenses, which requires public entities to disclose, within the footnotes to the financial statements, disaggregated information about certain income statement expense captions, including disclosure of amounts for purchases of inventory, employee compensation, depreciation and intangible asset amortization, included in each relevant expense caption. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, our fiscal 2028, and interim periods within fiscal years beginning after December 15, 2027, our fiscal 2029, on a prospective basis, with early adoption and retrospective application permitted. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statement disclosures in our Form 10-K for fiscal 2028 and periodic reports thereafter.

"One Big Beautiful Bill Act"

On July 4, 2025, the “One Big Beautiful Bill Act” (the “Act”) was enacted into law. The Act included changes to U.S. tax law that were effective for us beginning with our quarter ending September 28, 2025. These changes included provisions allowing retroactive accelerated tax deductions for qualified property that resulted in an insignificant tax benefit for fiscal 2025 and are expected to have a similar impact in fiscal 2026.

Note 2 — Acquisitions

General

We generally pursue business combinations to strengthen our position in existing markets, increase our market share and product offerings and expand into new markets. Acquisitions are accounted for under the acquisition method of accounting. For each acquisition, the excess of the purchase consideration over the fair value of the net assets acquired and liabilities assumed is recorded as goodwill, which generally represents the combined value of our existing resources with the organizational talent of the acquired companies’ respective management teams to maximize efficiencies, market share growth and overall financial performance. For each acquisition, we complete our allocation of purchase price to the fair values of acquired assets and liabilities within a one-year measurement period.

For each acquisition completed in fiscal 2025 and fiscal 2026, the results of operations since the acquisition date and the assets are included in our Water Treatment segment, with the exception of one immaterial acquisition in the second quarter of fiscal 2026 that was in our Food & Health Sciences segment. Costs associated with each acquisition were not material and were expensed as incurred.

Fiscal 2026 Acquisitions

Acquisition of WaterSurplus, Inc.: On April 25, 2025, we acquired substantially all of the assets and assumed certain liabilities of Surplus Management, Inc. d/b/a WaterSurplus (“WaterSurplus”) for an initial purchase price of approximately $149.9 million under the terms of an asset purchase agreement by and among WaterSurplus and related entities and their shareholders, Panther Acquisition Corporation, and Hawkins, Inc., as well as a related real estate purchase agreement. In addition, we may be obligated to pay an additional earnout amount based on a target of accumulated gross profit for the first five years after the acquisition. The maximum earnout liability of $53.7 million was discounted and recorded at the estimated present value of $43.0 million. WaterSurplus is based in Rockford, IL and delivers sustainable water treatment solutions to customers throughout the United States.

The total purchase price, including the estimated fair value of $43.0 million for the earnout liability, was allocated as follows: $76.0 million to customer relationships, to be amortized over 15 years; $6.2 million to trade names, to be amortized over 15 years; $12.0 million to technology, to be amortized over 10 years; $82.6 million to goodwill; $12.9 million to property, plant and equipment; and the remaining amount of $3.2 million to net working capital. The goodwill recognized as a result of this acquisition is expected to be deductible for tax purposes. We have completed the purchase price allocation. The results of operations since the acquisition date and the assets are included in our Water Treatment segment. Costs associated with this transaction were not material and were expensed as incurred.

The following pro forma information has been prepared as if the WaterSurplus acquisition and the borrowing that financed the acquisition had occurred as of the beginning of the earliest fiscal period presented. The unaudited pro forma information is not necessarily indicative of what our consolidated results of operations actually would have been had the acquisition occurred at the beginning of each fiscal year, nor is it indicative of our future operational results.


	Three months ended				Nine months ended
(in thousands, except per share data)	December 28, 2025		December 29, 2024		December 28, 2025		December 29, 2024
Pro forma sales	$	244,080	$	237,458	$	819,941	$	756,079
Pro forma net income	$	14,312	$	13,234	$	66,239	$	61,774

Pro forma basic earnings per share	$	0.69	$	0.64	$	3.20	$	2.97
Pro forma diluted earnings per share	$	0.69	$	0.63	$	3.18	$	2.96

The unaudited pro forma financial information above is adjusted to reflect the following: (a) interest expense, including amortization of debt issuance costs, related to the approximately $150 million of debt used to fund the acquisition and related purchase of real estate; (b) amortization expense related to the preliminary $94 million of identifiable intangible assets recognized in conjunction with the acquisition; (c) depreciation expense as adjusted for adjusted fixed asset values; (d) remeasurement of the earnout payable at fair value; (e) adjustment to cost of goods sold for the inventory step-up adjustment; (f) adjustment for acquisition costs incurred; (g) elimination of net interest previously reflected on WaterSurplus’ financial statements; and (h) recording income taxes at our effective tax rate for each period.

Sales of WaterSurplus of $8.4 million for the three months ended December 28, 2025 and $26.5 million for the nine months ended December 28, 2025 were included in our condensed consolidated statements of income. Operating loss of WaterSurplus of $1.6 million for the three months ended December 28, 2025 and $1.8 million for the nine months ended December 28, 2025 was also included in our condensed consolidated statements of income.

Inclusive of five additional immaterial acquisitions not discussed above, total cash consideration for the acquisitions completed in the nine months ended December 28, 2025 was $167.1 million.

Fiscal 2025 Acquisitions

We completed four acquisitions in fiscal 2025, including the previously announced acquisitions shown below.

Amerochem Corporation ("Amerochem") was acquired on January 31, 2025 for $44.0 million. Located in North Carolina, Amerochem distributed water treatment chemicals and equipment to its customers located primarily in North Carolina.

Waterguard, Inc. ("Waterguard") was acquired on October 31, 2024 for $18.0 million. Located in North Carolina, Waterguard distributed water treatment chemicals and equipment to its customers located primarily in North Carolina.

Intercoastal Trading, Inc. ("Intercoastal") was acquired on June 3, 2024 for $22.0 million. Located in Maryland, Intercoastal distributed water treatment chemicals and equipment to its customers in Maryland, Delaware, and Virginia.

Inclusive of one immaterial acquisition not discussed above, total cash consideration for the 2025 acquisitions completed in the nine months ended December 29, 2024 was $43.4 million.

Note 3 - Revenue

Our revenue arrangements generally consist of a single performance obligation to transfer promised goods or services. We disaggregate revenues from contracts with customers by operating segments as well as types of products sold. Reporting by operating segment is pertinent to understanding our revenues, as it aligns to how we review the financial performance of our operations. The following tables disaggregate external customer net sales by major revenue stream as reviewed internally for the three and nine months ended December 28, 2025 and December 29, 2024:


	Three months ended December 28, 2025
(In thousands)	Water Treatment		Food & Health Sciences		Industrial Solutions		Total
Manufactured, blended, repackaged products or equipment (1)	$	106,983	$	—	$	40,981	$	147,964
Bulk products (2)	12,044		—		11,237		23,281
Nutrition	—		24,579		—		24,579
Food	—		29,158		—		29,158
Pharmaceutical	—		7,322		—		7,322
Agricultural	—		8,362		—		8,362
Other	1,460		583		1,371		3,414
Total external customer sales	$	120,487	$	70,004	$	53,589	$	244,080

	Three months ended December 29, 2024
(In thousands)	Water Treatment		Food & Health Sciences		Industrial Solutions		Total
Manufactured, blended, repackaged products or equipment (1)	$	89,367	$	—	$	35,572	$	124,939
Bulk products (2)	9,136		—		12,100		21,236
Nutrition	—		25,993		—		25,993
Food	—		34,365		—		34,365
Pharmaceutical	—		6,864		—		6,864
Agricultural	—		9,834		—		9,834
Other	1,249		674		1,051		2,974
Total external customer sales	$	99,752	$	77,730	$	48,723	$	226,205

	Nine months ended December 28, 2025
(In thousands)	Water Treatment		Food & Health Sciences		Industrial Solutions		Total
Manufactured, blended or repackaged products (1)	$	380,846	$	—	$	125,766	$	506,612
Bulk products (2)	36,295		—		34,826		71,121
Nutrition	—		75,204		—		75,204
Food	—		97,906		—		97,906
Pharmaceutical	—		19,549		—		19,549
Agricultural	—		37,494		—		37,494
Other	3,820		1,942		4,138		9,900
Total external customer sales	$	420,961	$	232,095	$	164,730	$	817,786

	Nine months ended December 29, 2024
(In thousands)	Water Treatment		Food & Health Sciences		Industrial Solutions		Total
Manufactured, blended or repackaged products (1)	$	307,901	$	—	$	114,686	$	422,587
Bulk products (2)	29,809		—		34,874		64,683
Nutrition	—		78,411		—		78,411
Food	—		102,137		—		102,137
Pharmaceutical	—		18,632		—		18,632
Agricultural	—		33,133		—		33,133
Other	3,746		1,912		3,872		9,530
Total external customer sales	$	341,456	$	234,225	$	153,432	$	729,113

(1)This line includes our non-bulk specialty products in our Water Treatment and Industrial Solutions segments that we either manufacture, blend, repackage, resell in their original form, or direct ship to our customers in smaller quantities, and equipment and services we provide for our customers.

(2)This line includes bulk products in our Water Treatment and Industrial Solutions segments that we do not modify in any way, but receive, store, and ship from our facilities, or direct ship to our customers in large quantities.

Note 4 – Earnings per Share

Basic earnings per share (“EPS”) is computed by dividing net earnings by the weighted-average number of common shares outstanding. Diluted EPS includes the dilutive impact of incremental shares assumed to be issued as performance units and restricted stock.

Basic and diluted EPS were calculated using the following:


	Three months ended		Nine months ended
	December 28, 2025	December 29, 2024	December 28, 2025	December 29, 2024
Weighted-average common shares outstanding—basic	20,740,284	20,766,764	20,731,837	20,780,213
Dilutive impact of performance units and restricted stock	103,696	108,623	118,884	122,243
Weighted-average common shares outstanding—diluted	20,843,980	20,875,387	20,850,721	20,902,456

For each of the periods presented, there were no shares excluded from the calculation of weighted-average common shares for diluted EPS.

Note 5 – Fair Value Measurements

Our financial assets and liabilities are measured at fair value at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The carrying value of cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these instruments. Because of the variable-rate nature of our debt under our credit facility, our debt also approximates fair value.

Assets and Liabilities Measured at Fair Value on a Recurring Basis. The fair value hierarchy requires the use of observable market data when available. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Our assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

Our financial assets that are measured at fair value on a recurring basis are an interest rate swap and assets held in a deferred compensation retirement plan. Both of these assets are classified as long-term assets on our balance sheet, with the portion of the deferred compensation retirement plan assets expected to be paid within twelve months classified as current assets. The fair value of the interest rate swap is determined by the respective counterparties based on interest rate changes. Interest rate swaps are valued based on observable interest rate yield curves for similar instruments. The deferred compensation plan assets relate to contributions made to a non-qualified compensation plan on behalf of certain employees who are classified as “highly compensated employees” as determined by IRS guidelines. The assets are part of a rabbi trust and the funds are held in mutual funds. The fair value of the deferred compensation is based on the quoted market prices for the mutual funds at the end of the period.

The earnout liabilities recorded in conjunction with the acquisitions of Water Solutions Unlimited, Inc. ("Water Solutions") (acquired during fiscal 2024) and WaterSurplus are based upon achieving certain targets. The Water Solutions earnout is based on a target of adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) in year three of the acquisition. The earnout liability was valued based upon a risk-neutral pricing analysis within a Monte Carlo simulation framework, which is a Level 3 input. The WaterSurplus earnout liability is based on a target of accumulated gross profit for the first five years of the acquisition. The earnout liability was discounted and recorded at the present value of the anticipated, maximum payout amount, which is a Level 3 input. The earnout liabilities are adjusted to fair value at each reporting date until settled. Changes in fair value are included in selling, general and administrative expenses in our Condensed Consolidated Statements of Income.

The following tables summarize the balances of assets and liabilities measured at fair value on a recurring basis as of December 28, 2025 and March 30, 2025.


(In thousands)		December 28, 2025		March 30, 2025
Assets
Deferred compensation plan assets	Level 1	$	14,808	$	11,723
Interest rate swap	Level 2	$	1,281	$	2,373
Liabilities
WaterSurplus earnout liability	Level 3	$	44,427	$	—
Water Solutions earnout liability	Level 3	$	6,410	$	12,604

The changes in the earnout liability measured at fair value using Level 3 inputs were as follows:











(In thousands)
Earnout liability at March 30, 2025		$	12,604
Addition for acquisition of WaterSurplus	Level 3	$	43,000
Fair value adjustments to WaterSurplus earnout liability	Level 3	$	1,427
Fair value adjustments to Water Solutions earnout liability	Level 3	$	(6,194)
Earnout liability at December 28, 2025		$	50,837

Note 6 – Inventories

Inventories at December 28, 2025 and March 30, 2025 consisted of the following:


	December 28, 2025		March 30, 2025
(In thousands)
Inventory (FIFO basis)	$	109,541	$	106,357
LIFO reserve	(23,608)		(22,845)
Net inventory	$	85,933	$	83,512

We use the last in, first out (“LIFO”) method of valuing the majority of our inventory, which causes the most recent product costs to be recognized in our condensed consolidated statements of income.

Note 7 – Goodwill and Intangible Assets

The carrying amounts of goodwill for each of our three reportable segments were as follows:


(In thousands)	Water Treatment		Food & Health Sciences		Industrial Solutions		Total
Balance as of March 30, 2025	$	83,968	$	46,149	$	5,292	$	135,409
Addition due to acquisitions	86,904		722		—		87,626
Balance as of December 28, 2025	$	170,872	$	46,871	$	5,292	$	223,035

The following is a summary of our identifiable intangible assets as of December 28, 2025 and March 30, 2025:


	December 28, 2025						March 30, 2025
(In thousands)	Gross Amount		Accumulated Amortization		Net		Gross Amount		Accumulated Amortization		Net
Finite-life intangible assets
Customer relationships	$	283,654	$	(70,538)	$	213,116	$	198,364	$	(57,311)	$	141,053
Trademarks and trade names	$	21,622	$	(9,020)	$	12,602	$	14,970	$	(7,368)	$	7,602
Other finite-life intangible assets	16,526		(5,090)		11,436		4,410		(4,171)		239
Total finite-life intangible assets	321,802		(84,648)		237,154		217,744		(68,850)		148,894
Indefinite-life intangible assets	1,227		—		1,227		1,227		—		1,227
Total intangible assets	$	323,029	$	(84,648)	$	238,381	$	218,971	$	(68,850)	$	150,121

Note 8 – Debt

We are party to a second amended and restated credit agreement with U.S. Bank National Association (“U.S. Bank”) as administrative agent, sole lead arranger and sole book runner, and the other lenders from time to time party thereto (collectively, the “Lenders”), dated as of March 31, 2022 (and as amended, restated or modified from time to time, the “Credit Agreement”). A Joinder, Consent and Second Amendment dated April 25, 2025 increased the revolving commitment under the Credit Agreement to provide us with senior secured revolving credit facilities (the “Revolving Loan Facility”) totaling $400.0 million. A Third Amendment dated October 15, 2025, modified terms related to qualified receivables transactions, as defined in the Credit Agreement. The Revolving Loan Facility includes a $10.0 million letter of credit subfacility and $25.0 million swingline subfacility.

In addition to using the debt proceeds from the Revolving Loan Facility to pay off the existing debt at the time, we drew approximately $150 million of additional proceeds to acquire substantially all of the assets of WaterSurplus as discussed in Note 2. We may use other proceeds from the Revolving Loan Facility for working capital, capital expenditures, restricted payments and other acquisitions permitted under the Credit Agreement, and other general corporate purposes.

We paid fees of approximately $1.0 million associated with the April refinancing. The Revolving Loan Facility is scheduled to mature on April 25, 2030.

Borrowings under the Revolving Loan Facility bear interest at a variable rate based on term SOFR plus a margin. We have an interest rate swap in place to manage the risk associated with a portion of our variable-rate debt. The notional amount of the swap agreement is $60 million. At December 28, 2025, the effective interest rate on our borrowings was 4.8%.

Debt at December 28, 2025 and March 30, 2025 consisted of the following:


	December 28, 2025		March 30, 2025

(In thousands)

Senior secured revolving loan	$	264,000	$	149,000

Less: unamortized debt issuance costs	(813)		(181)
Total debt, net of debt issuance costs	263,187		148,819
Less: current portion of long-term debt	(9,812)		(9,913)
Total long-term debt	$	253,375	$	138,906

Note 9 – Income Taxes

We are subject to U.S. federal income tax as well as income tax of multiple state jurisdictions. The tax years prior to our fiscal year ended April 3, 2022 are closed to examination by the Internal Revenue Service, and with few exceptions, state and local income tax jurisdictions. Our effective income tax rate was approximately 27% for the three months ended December 28, 2025 and 26% for the three months ended December 29, 2024, and approximately 26% for both the nine months ended December 28, 2025 and December 29, 2024. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, and state taxes.

Note 10 – Share-Based Compensation

Performance-Based Restricted Stock Units. Our Board of Directors (the “Board”) approved a performance-based equity compensation arrangement for our executive officers during the first quarters of each of fiscal 2026 and fiscal 2025. These performance-based arrangements provide for the grant of performance-based restricted stock units under our 2019 Equity Incentive Plan (the "2019 Plan") that represent a possible future issuance of restricted shares of our common stock based on a pre-tax income target for the applicable fiscal year. The actual number of restricted shares to be issued to each executive officer is determined when our final financial information becomes available after the applicable fiscal year and will be between zero shares and 58,353 shares in the aggregate for fiscal 2026. The restricted shares issued, if any, will fully vest approximately two years after the last day of the fiscal year on which the performance is based. We are recording the compensation expense for the outstanding performance share units and the converted restricted stock over the life of the awards.

The following table represents the restricted stock activity for the nine months ended December 28, 2025:


	Shares	Weighted- Average Grant Date Fair Value
Unvested at beginning of period	137,247	$	61.49
Granted	61,418	119.67
Vested	(61,819)	43.06

Unvested at end of period	136,846	$	95.93

We recorded compensation expense related to performance share units and restricted stock of $1.3 million for both the three months ended December 28, 2025 and December 29, 2024. We recorded compensation expense related to performance share units and restricted stock of $4.9 million for the nine months ended December 28, 2025 and $3.9 million for the nine months ended December 29, 2024. Substantially all of the compensation expense was recorded in selling, general and administrative expenses in the condensed consolidated statements of income.

Restricted Stock Awards. As part of their retainer, our directors, other than the Chief Executive Officer, receive restricted stock for their Board services. The restricted stock awards are under our 2019 Plan and are generally expensed over a one-year vesting period, based on the market value on the date of grant. As of December 28, 2025, there were 4,396 shares of restricted stock with an average grant date fair value of $159.16 outstanding under this program. Compensation expense related to restricted stock awards to the Board was $0.2 million for both the three months ended December 28, 2025 and December 29, 2024. Compensation expense related to restricted stock awards to the Board was $0.5 million for both the nine months ended December 28, 2025 and December 29, 2024.

During the nine months ended December 28, 2025, certain employees from the WaterSurplus acquisition received restricted stock awards under the 2019 Plan, primarily to incentivize their continued service. The restricted stock awards will be expensed over a three-year vesting period, based on the market value on the date of grant. As of December 28, 2025, there were 8,713 shares of restricted stock with an average grant date fair value of $142.10 outstanding under this program. Compensation expense related to restricted stock awards to certain WaterSurplus employees was $0.1 million for the three months ended December 28, 2025 and $0.2 million nine months ended December 28, 2025. No expense was recorded for the three and nine months ended December 29, 2024.

Note 11 – Share Repurchase Program

Our Board has authorized the repurchase of up to 2.6 million shares of our outstanding common shares. The shares may be repurchased on the open market or in privately negotiated transactions subject to applicable securities laws and regulations. Upon purchase of the shares, we reduce our common stock for the par value of the shares with the excess applied against additional paid-in capital. During the three and nine months ended December 28, 2025, no shares were repurchased. During the three months ended December 29, 2024, no shares were repurchased, and during the nine months ended December 29, 2024, we repurchased 105,541 shares at an aggregate purchase price of $9.1 million. As of December 28, 2025, 731,544 shares remained available to be repurchased under the share repurchase program.

Note 12 – Commitments and Contingencies

Environmental Remediation. In the fourth quarter of fiscal 2024, we recorded a liability of $7.7 million related to estimated remediation expenses associated with perchlorinated biphenyls ("PCBs") discovered in the soil at our Rosemount, MN facility during our expansion project. We acquired the property, which had prior heavy industrial use, in fiscal 2012. While the source of the PCBs is unknown, we have never brought PCBs onto the property or used PCBs on the site. The liability is not discounted as management expects to incur these expenses within the next twelve months. Given the many uncertainties involved in assessing environmental claims, our reserves may prove to be insufficient. While it is possible that additional expense related to the remediation will be incurred in future periods if currently unknown issues arise, we are unable to estimate the extent of financial impact related to any such unknown issues. No expenses were charged against this liability during both the three and nine months ended December 28, 2025 and December 29, 2024.

Note 13 – Segment Information

Effective beginning with the first fiscal quarter of fiscal 2026, we realigned our reporting segments to reflect organizational changes made and to reflect the way we manage our operations and allocate resources. We believe this realignment better reflects the value our company provides to our customers and our evolution from a bulk commodity distributor into a specialty ingredients company. In fiscal 2026, we organize and manage our business by the following three segments, each of which meets the definition of reportable segments under ASC 280-10, Segment Reporting: Water Treatment, Food & Health Sciences, and Industrial Solutions. These segments are defined primarily by product and type of customer.

Our chief operating decision-maker (CODM), who is our President and Chief Executive Officer, regularly reviews the consolidated financial statements in their entirety and financial information at the reportable segment level. The CODM uses operating income and considers budget-to-actual variances on a quarterly basis when making decisions about the allocation of operating and capital resources to each segment. The CODM also uses segment operating income for evaluating pricing strategy, to assess the performance of each segment by comparing the results of each segment with one another, and in determining the compensation of certain employees. The CODM has ultimate responsibility for enterprise decisions and making resource allocation decisions for the Company and the segments.

•Our Water Treatment segment specializes in providing chemicals, products, equipment, services and solutions for potable water, municipal and industrial wastewater, industrial process water, non-residential swimming pool water and agricultural water. This segment has the resources and flexibility to treat systems ranging in size from a single small well to a multi-million-gallon-per-day facility.

•Our Food & Health Sciences segment specializes in processing and formulation solutions as well as ingredient distribution to manufacturers in the nutrition, food, pharmaceutical, and agricultural markets. This segment offers a diverse product portfolio including base chemistry, acid based reactions, minerals, vitamins and amino acids, excipients, botanicals and herbs, sweeteners and enzymes, fertilizers, and food-grade and pharmaceutical salts and ingredients.

•Our Industrial Solutions segment specializes in providing industrial chemicals, products and services to industries such as industrial manufacturing, chemical processing, electronics, energy, plating, and surface finishing. This segment’s principal products are acids and alkalis.

The accounting policies of the segments are the same as those described in the summary of significant accounting policies. Product costs and expenses for each segment are based on actual costs incurred along with cost allocations of shared and centralized functions.

There are no intersegment sales and no operating segments have been aggregated.

In fiscal 2026 and 2025, none of our customers accounted for 10% or more of our total sales.

Summarized financial information for our reportable segments is presented and reconciled to consolidated financial information in the following tables:


(In thousands)	Water Treatment		Food & Health Sciences		Industrial Solutions		Total
Three months ended December 28, 2025:
Sales	$	120,487	$	70,004	$	53,589	$	244,080
Cost of sales - materials	(73,957)		(50,710)		(42,529)		(167,196)
Cost of sales - operational overhead	(16,976)		(5,447)		(3,648)		(26,071)
Gross profit	29,554		13,847		7,412		50,813
Selling, general, and administrative expenses	(16,715)		(8,166)		(3,376)		(28,257)
Operating income	12,839		5,681		4,036		22,556
Interest expense, net							(3,434)
Other income							459
Income tax expense							(5,269)
Net income							14,312
Identifiable assets*	564,689		244,038		132,946		941,673
Capital expenditures	8,021		2,941		3,359		14,321
Depreciation and amortization	7,902		3,290		2,218		13,410


(In thousands)	Water Treatment		Food & Health Sciences		Industrial Solutions		Total
Three months ended December 29, 2024:
Sales	$	99,752	$	77,730	$	48,723	$	226,205
Cost of sales - materials	(58,546)		(55,944)		(38,075)		(152,565)
Cost of sales - operational overhead	(15,350)		(5,497)		(4,369)		(25,216)
Gross profit	25,856		16,289		6,279		48,424
Selling, general, and administrative expenses	(16,058)		(7,761)		(3,542)		(27,361)
Operating income	9,798		8,528		2,737		21,063
Interest expense, net							(1,216)
Other income							436
Income tax expense							(5,262)
Net income							15,021
Identifiable assets*	124,713		306,859		242,334		673,906
Capital expenditures	4,361		2,113		2,248		8,722
Depreciation and amortization	4,808		3,151		2,152		10,111

Nine months ended December 28, 2025:
Sales	$	420,961	$	232,095	$	164,730	$	817,786
Cost of sales - materials	(251,930)		(169,677)		(130,508)		(552,115)
Cost of sales - operational overhead	(52,469)		(13,742)		(8,642)		(74,853)
Gross profit	116,562		48,676		25,580		190,818
Selling, general, and administrative expenses	(57,871)		(24,631)		(10,487)		(92,989)
Operating income	58,691		24,045		15,093		97,829
Interest expense, net							(10,535)
Other income							2,122
Income tax expense							(23,331)
Net income							66,085

Capital expenditures	22,614		7,728		8,321		38,663
Depreciation and amortization	22,660		9,704		6,599		38,963
Nine months ended December 29, 2024:
Sales	$	341,456	$	234,225	$	153,432	$	729,113
Cost of sales - materials	(195,807)		(168,545)		(120,321)		(484,673)
Cost of sales - operational overhead	(48,657)		(13,423)		(9,059)		(71,139)
Gross profit	96,992		52,257		24,052		173,301
Selling, general, and administrative expenses	(45,962)		(22,582)		(10,158)		(78,702)
Operating income	51,030		29,675		13,894		94,599
Interest expense, net							(3,906)
Other income							1,268
Income tax expense							(23,943)
Net income							68,018

Capital expenditures	15,910		6,695		7,403		30,008
Depreciation and amortization	13,673		9,362		6,333		29,368

*Unallocated assets not included, consisting primarily of cash and cash equivalents, prepaid expenses, and non-qualified deferred compensation plan assets of $34.9 million at December 28, 2025 and $33.3 million at December 29, 2024.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is a discussion and analysis of our financial condition and results of operations for the three and nine months ended December 28, 2025 as compared to the similar period ended December 29, 2024. This discussion should be read in conjunction with the condensed consolidated financial statements and notes to condensed consolidated financial statements included in this quarterly report on Form 10-Q and Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended March 30, 2025.

Overview

We derive substantially all of our revenues from the sale of water treatment solutions, specialty ingredients, and chemicals to our customers in a wide variety of industries. We began our operations primarily as a distributor of bulk chemicals with a strong customer focus. Over the years, we have maintained a strong customer focus and have expanded our business by increasing our sales of value-added and specialty ingredients, including manufacturing, blending, and repackaging certain products.

Business Acquisitions

We completed the following acquisitions in fiscal 2025 and the first nine months of fiscal 2026. The results of operations since the date of each acquisition and the assets, including goodwill associated with these acquisitions, are included in our Water Treatment segment with the exception of the MakWood lactate business which is included in our Food & Health Sciences segment. Certain acquisitions discussed below are not included in Note 2 to our Condensed Consolidated Financial Statements as they were not deemed to be material enough to warrant disclosure.

•On December 3, 2025, we acquired substantially all the assets and assumed certain liabilities of Redbird Chemical, Inc. (“Redbird”) for $4.6 million. Redbird distributed chemicals to its customers in eastern Texas within both the water treatment and industrial markets.

•On August 29, 2025, we acquired substantially all the assets and assumed certain liabilities of StillWaters Technology, Inc. ("StillWaters") for $4.3 million. StillWaters distributed water treatment chemicals and equipment for its customers in Alabama.

•On July 2, 2025, we acquired the lactate business of MakWood, Inc. for $1.9 million. We had previously been party to a Distribution Agreement with MakWood for certain lactate products under the Mak Lak trade name. This acquisition agreement terminated the Distribution Agreement, and resulted in our acquisition of the lactate distribution business, including the customer list and associated brand name.

•On July 1, 2025, we acquired substantially all the assets and assumed certain liabilities of PhillTech, LLC ("PhillTech") for $5.0 million. Located in Courtland, AL, PhillTech manufactured and distributed coagulants and corrosion control products for its water treatment customers.

•On June 13, 2025, we acquired substantially all the assets and assumed certain liabilities of Hendrickson Enterprises, LLC and Polymer Technologies, LLC (collectively, "Hendrickson") for approximately $1.5 million. Hendrickson distributed water treatment chemicals and equipment to its customers via direct shipments from suppliers.

•On April 25, 2025, we acquired substantially all of the assets and assumed certain liabilities of WaterSurplus and related entities for approximately $149.9 million paid at closing, with an additional amount payable as an earnout of up to $53.7 million based on cumulative gross profit for the first five years. WaterSurplus is located in Rockford, IL and delivers sustainable water treatment solutions to customers throughout the United States.

•In the fourth quarter of fiscal 2025, we acquired substantially all the assets and assumed certain liabilities of Amerochem for $44.0 million. Amerochem distributed water treatment chemicals and equipment to its customers primarily throughout North Carolina.

•In the third quarter of fiscal 2025, we acquired substantially all the assets and assumed certain liabilities of Water Guard for $18.0 million. Water Guard distributed water treatment chemicals and equipment to its customers primarily throughout North Carolina.

•In the first quarter of fiscal 2025, we acquired substantially all the assets and assumed certain liabilities of Wofford Water Service, Inc. for $3.4 million. Wofford distributed water treatment chemicals and equipment to customers mainly in Mississippi.

•In the first quarter of fiscal 2025, we acquired substantially all the assets and assumed certain liabilities of Intercoastal for $22.0 million. Intercoastal distributed water treatment chemicals and equipment to its customers in Maryland, Delaware and Virginia.

The aggregate annual revenue of these ten businesses acquired in fiscal 2025 and fiscal 2026 totaled approximately $116 million, as determined using the applicable twelve-month period preceding each respective acquisition date.

Change in Reporting Segments

Effective beginning with the first quarter of fiscal 2026, we realigned our reporting segments to better reflect how we manage our operations and allocate resources. We believe this realignment better reflects the value our company provides to our customers and our evolution from a bulk commodity distributor into a specialty ingredients company. We now organize and manage our business by the following three segments, each of which meets the definition of reportable segments under ASC 280-10, Segment Reporting: Water Treatment, Food & Health Sciences, and Industrial Solutions. These segments are defined primarily by product and type of customer. Information presented in this quarterly report has been recast to align with the new segments. Additional information regarding these new segments is set forth in Note 13 to our Condensed Consolidated Financial Statements.

Financial Results

We focus on operating income when evaluating our financial results as opposed to profitability as a percentage of sales, as sales dollars tend to fluctuate as raw material prices rise and fall. The costs for certain of our raw materials can rise or fall rapidly, causing fluctuations in gross profit as a percentage of sales.

We use the last in, first out (“LIFO”) method of valuing the majority of our inventory, which causes the most recent product costs to be recognized in our income statement. The LIFO inventory valuation method and the resulting cost of sales are consistent with our business practices of pricing to current chemical raw material prices.

We disclose the sales of our bulk commodity products as a percentage of total sales dollars for our Water Treatment and Industrial Solutions segments. Our definition of bulk commodity products includes products that we do not modify in any way, but receive, store, and ship from our facilities, or direct ship to our customers in large quantities. We disclose the percentage of our overall sales that consist of sales of bulk commodity products as these products are generally distributed and we do not add significant value to these products in comparison to our non-bulk products. Sales of these products are generally highly competitive and price sensitive. As a result, bulk commodity products generally have our lowest margins.

Results of Operations

The following table sets forth the percentage relationship of certain items to sales for the period indicated:


	Three months ended				Nine months ended
	December 28, 2025		December 29, 2024		December 28, 2025		December 29, 2024
Sales	100.0	%	100.0	%	100.0	%	100.0	%
Cost of sales	(79.2)	%	(78.6)	%	(76.7)	%	(76.2)	%

Gross profit	20.8	%	21.4	%	23.3	%	23.8	%
Selling, general and administrative expenses	(11.6)	%	(12.1)	%	(11.4)	%	(10.8)	%
Operating income	9.2	%	9.3	%	11.9	%	13.0	%
Interest expense, net	(1.4)	%	(0.5)	%	(1.3)	%	(0.5)	%
Other income	0.2	%	0.2	%	0.3	%	0.2	%
Income before income taxes	8.0	%	9.0	%	10.9	%	12.7	%
Income tax expense	(2.2)	%	(2.3)	%	(2.9)	%	(3.3)	%
Net income	5.8	%	6.7	%	8.0	%	9.4	%

Three Months Ended December 28, 2025 Compared to Three Months Ended December 29, 2024

Sales

Sales were $244.1 million for the three months ended December 28, 2025, an increase of $17.9 million, or 8%, from sales of $226.2 million in the same period a year ago. Sales in our Water Treatment and Industrial Solutions segments both grew by more than 10%, while sales in our Food & Health Sciences segment decreased 10%.

Water Treatment Segment. Water Treatment segment sales increased $20.7 million, or 21%, to $120.5 million for the three months ended December 28, 2025, from sales of $99.8 million in the same period a year ago. Sales of bulk commodity products in the Water Treatment segment were approximately 10% of sales dollars in the current quarter and 9% in the same

period a year ago. Sales increased as a result of approximately $19 million of added sales from acquired businesses as well as improved pricing on certain of our products in our legacy businesses on slightly increased sales volumes.

Food & Health Sciences Segment. Food & Health Sciences segment sales decreased $7.7 million, or 10%, to $70.0 million for the three months ended December 28, 2025, from sales of $77.7 million in the same period a year ago. Sales dollars decreased primarily as a result of decreased volumes of our food, health & nutrition, and agricultural products.

Industrial Solutions Segment. Industrial Solutions segment sales increased $4.9 million, or 10%, to $53.6 million for the three months ended December 28, 2025, from sales of $48.7 million in the same period a year ago. Sales of bulk commodity products in the Industrial Solutions segment were approximately 21% of sales dollars in the current quarter and 25% in the same period a year ago. Sales increased primarily as a result of increased sales volumes of certain of our manufactured, blended and repackaged products.

Gross Profit

Gross profit increased $2.4 million, or 5%, to $50.8 million, or 21% of sales, for the three months ended December 28, 2025, from $48.4 million, or 21% of sales, in the same period a year ago. During the current quarter, the LIFO reserve decreased, and gross profit increased, by $0.2 million. In the same period a year ago, the LIFO reserve decreased, and gross profit increased, by $0.8 million.

Water Treatment Segment. Gross profit for the Water Treatment segment increased $3.7 million, or 14%, to $29.6 million, or 25% of sales, for the three months ended December 28, 2025, from $25.9 million, or 26% of sales, in the same period a year ago. Gross profit increased primarily as a result of increased sales from our acquired businesses as well as increased sales in our legacy business.

Food & Health Sciences Segment. Gross profit for the Food & Health Sciences segment decreased $2.5 million, or 15%, to $13.8 million, or 20% of sales, for the three months ended December 28, 2025, from $16.3 million, or 21% of sales, in the same period a year ago. Gross profit decreased primarily as a result of the decrease in sales.

Industrial Solutions Segment. Gross profit for the Industrial Solutions segment increased $1.1 million, or 18%, to $7.4 million, or 14% of sales, for the three months ended December 28, 2025, from $6.3 million, or 13% of sales, in the same period a year ago. Gross profit increased as a result of the increase in sales.

Selling, General and Administrative Expenses

Selling, general and administrative (“SG&A”) expenses increased $0.9 million, or 3%, to $28.3 million, or 12% of sales, for the three months ended December 28, 2025, from $27.4 million, or 12% of sales, in the same period a year ago. This included $5.4 million due to added costs from the acquired businesses in our Water Treatment segment, largely offset by a year-over-year reduction of $4.6 million due to a fair value adjustment recorded to the Water Solutions earnout liability as a result of a change in projected estimates related to the earnout target. The primary components of the $5.4 million of costs related to the acquired businesses were personnel and operating costs, $2.3 million of intangible amortization and $0.5 million of fair value accretion on the WaterSurplus earnout liability.

Operating Income

Operating income increased $1.5 million, or 7%, to $22.6 million, or 9% of sales, for the three months ended December 28, 2025, from $21.1 million, or 9% of sales, in the same period a year ago due to the combined impact of the factors discussed above.

Interest Expense, Net

Interest expense increased $2.2 million to $3.4 million for the three months ended December 28, 2025 compared to $1.2 million in the same period a year ago. Interest expense increased due to increased borrowings in the current year, primarily to fund the acquisition of WaterSurplus.

Other Income

Other income was $0.5 million for the three months ended December 28, 2025 and the same period a year ago. The income represents gains recorded on investments held for our non-qualified deferred compensation plan. The amounts recorded as a gain were offset by similar amounts recorded as an increase to compensation expense within SG&A expenses.

Income Tax Provision

Our effective income tax rate was approximately 27% the three months ended December 28, 2025 and 26% for the same period a year ago. The effective tax rate in the prior year period was impacted by favorable tax provision adjustments recorded. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, and state taxes. Our effective tax rate for the full year is expected to be approximately 26% to 27%.

Nine Months Ended December 28, 2025 Compared to Nine months ended December 29, 2024

Sales

Sales were $817.8 million for the nine months ended December 28, 2025, an increase of $88.7 million, or 12%, from sales of $729.1 million in the same period a year ago. Sales from our Water Treatment and Industrial Solutions segments grew 7% and 23%, respectively, while our Food and Health Sciences segment declined by 1%.

Water Treatment Segment. Water Treatment segment sales increased $79.5 million, or 23%, to $421.0 million for the nine months ended December 28, 2025, from sales of $341.5 million in the same period a year ago. Sales of bulk commodity products in the Water Treatment segment were approximately 9% of sales dollars in both the current period and in the same period a year ago. Sales increased as a result of approximately $70 million of added sales from acquired businesses as well as improved pricing and increased sales volumes on certain of our products in our legacy business.

Food & Health Sciences. Food & Health Sciences sales decreased $2.1 million or 1%, to $232.1 million for the nine months ended December 28, 2025, from sales of $234.2 million in the same period a year ago. Sales of our agricultural products increased $4.4 million due to increased volumes, partially offset by declines in some of our other product lines as a result of lower selling prices driven by competitive pricing pressures.

Industrial Solutions Segment. Industrial Solutions segment sales increased $11.3 million, or 7%, to $164.7 million for the nine months ended December 28, 2025, from sales of $153.4 million in the same period a year ago. Sales of bulk commodity products in the Industrial Solutions segment were approximately 21% of sales dollars in the current period and 23% in the same period a year ago. Sales increased primarily as a result of increased sales volumes of certain of our manufactured, blended and repackaged products.

Gross Profit

Gross profit increased $17.5 million, or 10%, to $190.8 million, or 23% of sales, for the nine months ended December 28, 2025, from $173.3 million, or 24% of sales, in the same period a year ago. During the current period, the LIFO reserve increased, and gross profit decreased, by $0.8 million due primarily to a projected increase in certain commodity volumes and costs at year end. In the same period a year ago, the LIFO reserve decreased, and gross profit increased, by $0.3 million.

Water Treatment Segment. Gross profit for the Water Treatment segment increased $19.6 million, or 20%, to $116.6 million, or 28% of sales, for the nine months ended December 28, 2025, from $97.0 million, or 28% of sales, in the same period a year ago. Gross profit increased primarily as a result of increased sales from our acquired businesses, as well as increased sales in our legacy business.

Food & Health Sciences. Gross profit for the Food & Health Sciences segment decreased $3.6 million, or 7% to $48.7 million, or 21% of sales, for the nine months ended December 28, 2025, from $52.3 million, or 22% of sales, in the same period a year ago. Gross profit decreased primarily as a result of the reduction in sales as well as lower selling prices resulting from competitive pricing pressures.

Industrial Solutions Segment. Gross profit for our Industrial Solutions segment increased $1.5 million, or 6%, to $25.6 million, or 16% of sales, for the nine months ended December 28, 2025, from $24.1 million, or 16% of sales, in the same period a year ago. Gross profit increased as a result of the increase in sales.

Selling, General and Administrative Expenses

SG&A expenses increased $14.3 million, or 18%, to $93.0 million, or 11% of sales, for the nine months ended December 28, 2025, from $78.7 million, or 11% of sales, in the same period a year ago. This included $16.0 million in added costs from the acquired businesses in our Water Treatment segment, partially offset by a year-over-year reduction of $7.2 million due to a fair value adjustment recorded to the Water Solutions earnout liability due to a change in projected estimates related to the earnout target. The primary components of the $16.0 million in costs related to acquired businesses were personnel and operating costs, $6.8 million of amortization of intangibles, $1.4 million of fair value accretion on the WaterSurplus earnout liability and $1.2 million of acquisition costs. In addition, a year-over-year increase of $0.9 million in compensation expense related to our non-qualified deferred compensation plan increased SG&A expenses, with the offset in Other Income. SG&A expenses also increased due to increases in other variable costs, including variable pay and personnel costs.

Operating Income

Operating income increased $3.2 million, or 3%, to $97.8 million, or 12% of sales, for the nine months ended December 28, 2025, from $94.6 million, or 13% of sales, in the same period a year ago due to the combined impact of the factors discussed above.

Interest Expense, Net

Interest expense increased $6.6 million to $10.5 million for the nine months ended December 28, 2025, from $3.9 million in the same period a year ago. Interest expense increased due to increased borrowings in the current year, primarily to fund the acquisition of WaterSurplus.

Other Income

Other income was $2.1 million for the nine months ended December 28, 2025 compared to $1.3 million in the same period a year ago. The income represents gains recorded on investments held for our non-qualified deferred compensation plan. The amounts recorded as a gain were offset by similar amounts recorded as an increase to compensation expense within SG&A expenses.

Income Tax Provision

Our effective income tax rate was 26% for both the nine months ended December 28, 2025 and the same period a year ago. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, and state taxes. Our effective tax rate for the full year is currently expected to be approximately 26% to 27%.

Liquidity and Capital Resources

Cash was $8.2 million at December 28, 2025, an increase of $3.1 million as compared with the $5.1 million available as of March 30, 2025.

Cash provided by operating activities was $106.6 million for the nine months ended December 28, 2025, compared to cash provided by operating activities of $80.3 million in the same period a year ago. The year-over-year increase in cash provided by operating activities in the current period was primarily driven by favorable year-over-year changes in trade receivables and inventories compared to the same period a year ago. Due to the nature of our operations, which includes purchases of large quantities of bulk chemicals, the timing of purchases can result in significant changes in working capital investment and the resulting operating cash flow.

Cash used in investing activities was $204.6 million for the nine months ended December 28, 2025, compared to $72.8 million in the same period a year ago. In the current period, we incurred acquisition spending of $167.1 million, including the acquisition of WaterSurplus for approximately $149.9 million paid at closing. Capital expenditures were $38.7 million for the current period, compared to $30.0 million in the same period a year ago. In the current period, we expended $4.2 million more for real estate and building expansions, contributing to the overall increase in capital expenditures compared to the prior year.

Cash provided by financing activities was $101.1 million for the nine months ended December 28, 2025, compared to $6.3 million of cash used in financing activities in the same period a year ago. Included in financing activities in the current period were net debt borrowings of $115.0 million, compared to net debt borrowings of $15.0 million in the same period a year ago. We drew approximately $150 million of the proceeds from the Revolving Loan Facility for the acquisition of WaterSurplus. In addition, we repurchased no common stock in the current period, compared to $9.1 million in the same period of the prior year.

We expect our cash balances and funds available under our credit facility, discussed below, along with cash flows generated from operations, will be sufficient to fund the cash requirements of our ongoing operations for the foreseeable future.

Our Board has authorized the repurchase of up to 2.6 million shares of our outstanding common shares. The shares may be purchased on the open market or in privately negotiated transactions subject to applicable securities laws and regulations. The primary objective of the share repurchase program is to offset the impact of dilution from issuances relating to employee and director equity grants and our employee stock purchase program. During the three and nine months ended December 28, 2025, we repurchased no shares of common stock. During the three months ended December 29, 2024, we repurchased no shares of common stock and during the nine months ended December 29, 2024, we repurchased 105,541 shares of common stock with an aggregate purchase price of $9.1 million. As of December 28, 2025, 731,544 shares remained available to be repurchased under the share repurchase program.

We are party to a second amended and restated credit agreement with U.S. Bank National Association (“U.S. Bank”) as administrative agent, sole lead arranger and sole book runner, and the other lenders from time to time party thereto (collectively, the “Lenders”), dated as of March 31, 2022 (as amended, restated or modified from time to time, the “Credit Agreement”). A Joinder, Consent and Second Amendment, dated April 25, 2025 increased the revolving commitment under the Credit Agreement to provide us with senior secured revolving credit facilities (the “Revolving Loan Facility”) totaling $400.0 million. A Third Amendment, dated October 15, 2025, modified terms related to qualified receivables transactions, as defined in the Credit Agreement. The Revolving Loan Facility includes a $10.0 million letter of credit subfacility and $25.0 million swingline subfacility. The Revolving Loan Facility has a five-year maturity date, maturing on April 25, 2030. The Revolving Loan Facility is secured by substantially all of our personal property assets and those of our subsidiaries. We may

use the amount available under the Revolving Loan Facility for working capital, capital expenditures, share repurchases, restricted payments and acquisitions permitted under the Credit Agreement, and other general corporate purposes.

Borrowings under the Revolving Loan Facility bear interest at a rate per annum equal to one of the following, plus, in both cases, an applicable margin based upon our leverage ratio: (a) Term SOFR, for an interest period of one, three or six months as selected by us, reset at the end of the selected interest period, or (b) a base rate determined by reference to the highest of (1) U. S. Bank’s prime rate, (2) the Federal Funds Effective Rate plus 0.5%, or (3) one-month Term SOFR for U.S. dollars plus 1.0%. The Term SOFR margin is between 1.0% and 1.85%, depending on our leverage ratio. The base rate margin is between 0.00% and 0.85%, depending on our leverage ratio. At December 28, 2025, the effective interest rate on our borrowings was 4.8%.

In addition to paying interest on the outstanding principal under the Revolving Loan Facility, we are required to pay a commitment fee on the unutilized commitments thereunder. The commitment fee is between 0.15% and 0.25%, depending on our leverage ratio.

Debt issuance costs paid to the Lenders are being amortized as interest expense over the term of the Credit Agreement. As of December 28, 2025, the unamortized balance of these costs was $0.8 million, and is reflected as a reduction of debt on our balance sheet.

The Credit Agreement requires that we maintain (a) a minimum fixed charge coverage ratio of 1.15 to 1.00 and (b) a maximum total cash flow leverage ratio of 3.5 to 1.0, subject to an election by us to increase the maximum total cash flow leverage ratio to 4.0 to 1.0 after certain Permitted Acquisitions subject to limitations set forth in the Credit Agreement. The Credit Agreement also contains other customary affirmative and negative covenants, including covenants that restrict our ability to incur additional indebtedness, dispose of significant assets, make certain investments, including any acquisitions other than permitted acquisitions, make certain payments, enter into sale and leaseback transactions, grant liens on its assets or rate management transactions, subject to certain limitations.

We are permitted to make distributions, pay dividends and repurchase shares so long as no default or event of default exists or would exist as a result thereof. We were in compliance with all covenants of the Credit Agreement as of December 28, 2025 and expect to remain in compliance with all covenants for the next 12 months.

The Credit Agreement contains customary events of default, the occurrence of which would permit the lenders to terminate their commitments and accelerate loans under the Revolving Loan Facility, including failure to make payments under the Revolving Loan Facility, failure to comply with covenants in the Credit Agreement and other loan documents, cross default to other material indebtedness, our failure to pay or discharge material judgments, bankruptcy, and change of control of the Company. The occurrence of an event of default would permit the lenders to terminate their commitments and accelerate loans under the Credit Facility.

We have in place an interest rate swap agreement to manage the risk associated with a portion of our variable-rate long-term debt. We do not utilize derivative instruments for speculative purposes. The interest rate swap involves the exchange of fixed-rate and variable-rate payments without the exchange of the underlying notional amount on which the interest payments are calculated. The notional amount of the swap agreement is $60 million, and it will terminate on May 1, 2027.

As part of our growth strategy, we have acquired businesses and may pursue acquisitions or other strategic relationships in the future that we believe will complement or expand our existing businesses or increase our customer base. We believe we could borrow additional funds under our current or new credit facilities or sell equity for strategic reasons or to further strengthen our financial position.

Critical Accounting Estimates

There have been no material changes in our critical accounting estimates, as disclosed in our Annual Report on Form 10-K for fiscal 2025.

Forward-Looking Statements

The information presented in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements have been made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. These statements are not historical facts, but rather are based on our current expectations, estimates and projections, and our beliefs and assumptions. Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will” and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control and are difficult to predict. These factors could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Additional information concerning potential factors that could affect future financial results is included in our Annual Report on Form 10-K for fiscal 2025. We caution you not to place undue reliance on these forward-looking statements, which reflect our

management’s view only as of the date of this Quarterly Report on Form 10-Q. We are not obligated to update these statements or publicly release the result of any revisions to them to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect the occurrence of unanticipated events.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are subject to the risk inherent in the cyclical nature of commodity chemical prices. However, we do not currently purchase forward contracts or otherwise engage in hedging activities with respect to the purchase of commodity chemicals. We attempt to pass changes in the cost of our materials to our customers. However, there are no assurances that we will be able to pass on the increases in the future.

We are exposed to market risks related to interest rates. Our exposure to changes in interest rates is primarily related to borrowings under our Revolving Loan Facility. We have in place an interest rate swap agreement to manage the risk associated with a portion of our variable-rate long-term debt. The interest rate swap involves the exchange of fixed-rate and variable-rate payments without the exchange of the underlying notional amount on which the interest payments are calculated. The notional amount of the swap agreement is $60.0 million, and it will terminate on May 1, 2027. As of December 28, 2025, a 25-basis point change in interest rates on our unhedged variable-rate debt would potentially increase or decrease our annual interest expense by approximately $0.5 million.

Other types of market risk, such as foreign currency risk, do not arise in the normal course of our business activities.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Quarterly Report on Form 10-Q, we conducted an evaluation, under supervision and with the participation of management, including the chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rules 13a-15 and 15d-15 of the Exchange Act. Based upon that evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of December 28, 2025. Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Exchange Act as controls and other procedures that are designed to ensure that information required to be disclosed by us in reports filed with the SEC under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or person performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control

There was no change in our internal control over financial reporting during the third quarter of fiscal 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

There are no material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which we or any of our subsidiaries are a party or of which any of our property is the subject.

ITEM 1A. RISK FACTORS

There have been no material changes to our risk factors from those disclosed in our Annual Report on Form 10-K for fiscal 2025.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Our Board has authorized the repurchase of up to 2.6 million shares of our outstanding common stock, initially approved on May 29, 2014 and subsequently amended from time to time. The repurchase plan has no expiration date. The shares may be purchased on the open market or in privately negotiated transactions subject to applicable securities laws and regulations. We did not repurchase any shares of our common stock during the three months ended December 28, 2025. The following table sets forth information concerning purchases of our common stock for the three months ended December 28, 2025:


Period	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of a Publicly Announced Plan or Program	Maximum Number of Shares that May Yet be Purchased under Plans or Programs
09/29/2025-10/26/2025	—	$	—	—	731,544
10/27/2025-11/23/2025	—	—		—	731,544
11/24/2025-12/28/2025	—	—		—	731,544
Total	—			—

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not Applicable.

ITEM 5. OTHER INFORMATION

None of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated any contract, instruction, or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the three months ended December 28, 2025.

ITEM 6. EXHIBITS

Exhibit

Description

Method of Filing

3.1

Restated Articles of Incorporation. (1)

Incorporated by Reference

3.2

Amended and Restated By-Laws. (2)

Incorporated by Reference

31.1

Certification by Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act.

Filed Electronically

31.2

Certification by Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act.

Filed Electronically

32.1

Section 1350 Certification by Chief Executive Officer.

Filed Electronically

32.2

Section 1350 Certification by Chief Financial Officer.

Filed Electronically

101

Financial statements from the Quarterly Report on Form 10-Q of Hawkins, Inc. for the period ended December 28, 2025 filed with the SEC on January 28, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL); (i) the Condensed Consolidated Balance Sheets at December 28, 2025 and March 30, 2025, (ii) the Condensed Consolidated Statements of Income for the three and nine months ended December 28, 2025 and December 29, 2024, (iii) the Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended December 28, 2025 and December 29, 2024, (iv) the Condensed Consolidated Statements of Shareholder's Equity for the three and nine months ended December 28, 2025 and December 29, 2024, (v) the Condensed Consolidated Statements of Cash Flows for the nine months ended December 28, 2025 and December 29, 2024, (vi) Notes to Condensed Consolidated Financial Statements and (vii) the information set forth in Part II, Item 5.

Filed Electronically

104

Cover Page Interactive Data File (embedded within the inline XBRL document)

Filed Electronically

(1)Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K dated February 26, 2021 and filed March 2, 2021.

(2)Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K dated October 28, 2009 and filed November 3, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


HAWKINS, INC.

By:						/s/ Jeffrey P. Oldenkamp
						Jeffrey P. Oldenkamp
						Executive Vice President and Chief Financial Officer
						(On behalf of the registrant as a duly authorized officer and as principal financial and accounting officer)

Dated: January 28, 2026


/s/ Patrick H. Hawkins
Patrick H. Hawkins
Chief Executive Officer and President
January 28, 2026